Corrado Advisors LLC Makes New $638,000 Investment in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Corrado Advisors LLC bought a new position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) during the 4th quarter, HoldingsChannel.com reports. The fund bought 55,209 shares of the company’s stock, valued at approximately $638,000.

Several other large investors also recently modified their holdings of GNOM. Raymond James Financial Services Advisors Inc. increased its stake in shares of Global X Genomics & Biotechnology ETF by 51.4% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 230,174 shares of the company’s stock worth $2,341,000 after purchasing an additional 78,164 shares during the last quarter. Prosperity Wealth Management Inc. purchased a new position in Global X Genomics & Biotechnology ETF in the 4th quarter valued at approximately $544,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Global X Genomics & Biotechnology ETF by 9.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 375,333 shares of the company’s stock valued at $3,817,000 after buying an additional 32,393 shares in the last quarter. Manhattan West Asset Management LLC grew its stake in Global X Genomics & Biotechnology ETF by 31.4% in the 3rd quarter. Manhattan West Asset Management LLC now owns 121,303 shares of the company’s stock valued at $1,234,000 after buying an additional 28,987 shares in the last quarter. Finally, Lido Advisors LLC grew its stake in Global X Genomics & Biotechnology ETF by 7.8% in the 3rd quarter. Lido Advisors LLC now owns 355,245 shares of the company’s stock valued at $3,613,000 after buying an additional 25,791 shares in the last quarter. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

Global X Genomics & Biotechnology ETF stock traded up $0.14 during mid-day trading on Tuesday, reaching $10.03. The company’s stock had a trading volume of 64,549 shares, compared to its average volume of 68,765. Global X Genomics & Biotechnology ETF has a 12-month low of $8.63 and a 12-month high of $13.33. The company has a market capitalization of $91.43 million, a P/E ratio of -4.28 and a beta of 1.30. The firm’s fifty day moving average price is $11.23 and its two-hundred day moving average price is $10.80.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.